Benchmarking Cornea Clinical Trials
Mark Hillen |
The cornea is no stranger to innovation and research – an incredible amount of time, effort and money has been invested in refractive surgery R&D over the years, and such procedures are almost uniformly safe and successful. But there’s more to the cornea than being a refractive surface that’s ripe for ablation – it’s the site of many diseases, from ocular surface disorders to endothelial dystrophies and everything in between. Treatment strategies span everything from excimer and femtosecond laser interventions, UV illumination combined with riboflavin application, stem cells, to even the topical administration fungal isolates like ciclosporin.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.